Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: A randomized controlled trial

American Journal of Psychiatry

Volumn 169, Issue 1, 2012, Pages 80-88

  Schneier, Franklin R ^a,b,c   Neria, Yuval ^a,b,c   Pavlicova, Martina ^a,b,c   Hembree, Elizabeth ^a,b,c   Suh, Eun Jung ^a,b,c   Amsel, Lawrence ^a,b,c   Marshall, Randall D ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROLONGED EXPOSURE THERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVOR; TERRORISM; TREATMENT RESPONSE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; UNITED STATES;

COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; NEW YORK CITY; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEPTEMBER 11 TERRORIST ATTACKS; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 84857202935     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11020321     Document Type: Article

References (41)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19 (Pubitemid 24028993)
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617-627 (Pubitemid 40973437)
3. Galea S, Vlahov D, Resnick H, Ahern J, Susser E, Gold J, Bucuvalas M, Kilpatrick D: Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol 2003; 158:514-524 (Pubitemid 37093227)
4. Difede J, Malta LS, Best S, Henn-Haase C, Metzler T, Bryant R, Marmar C: A randomized controlled clinical treatment trial for World Trade Center attack-related PTSD in disaster workers. J Nerv Ment Dis 2007; 195:861-865 (Pubitemid 351338934)
5. Marshall RD, Beebe KL, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158:1982-1988 (Pubitemid 33104102)
6. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62:860-868 (Pubitemid 33131172)
7. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 2007; 24:77-84 (Pubitemid 46516663)
8. American Psychiatric Association: Practice Guideline for Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder. Am J Psychiatry 2004; 161 (Nov suppl)
9. National Institute of Clinical Excellence: Posttraumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. London, National Collaborating Centre for Mental Health, 2005 (http://guidance.nice.org/CG26)
10. Forbes D, Creamer M, Bisson JI, Cohen JA, Crow BE, Foa EB, Friedman MJ, Keane TM, Kudler HS, Ursano RJ: A guide to guidelines for the treatment of PTSD and related conditions. J Trauma Stress 2010; 23:537-552
11. Institute of Medicine: Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. Washington, DC, National Academies Press, 2008
12. Ponniah K, Hollon SD: Empirically supported psychological treatments for adult acute stress disorder and posttraumatic stress disorder: a review. Depress Anxiety 2009; 26:1086-1109
13. Marshall RD, Cloitre M: Maximizing treatment outcome in posttraumatic stress disorder by combining psychotherapy with pharmacotherapy. Curr Psychiatry Rep 2000; 2:335-340
14. Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS, Pollack MH: Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther 2003; 41:1271-1276 (Pubitemid 37188368)
15. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG: Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006; 19:625-638 (Pubitemid 46424377)
16. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH: Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008; 69:400-405 (Pubitemid 351549392)
17. Hofmann SG, Sawyer AT, Korte KJ, Smits JA: Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic review. Int J Cogn Ther 2009; 2:160-175
18. Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA: Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther 1996; 34:669-673 (Pubitemid 26316912)
19. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM; The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995; 8:75-90
20. Spitzer RL, Williams JB, Gibbon M, First MB: Structured Clinical Interview for DSM-IV-Patient Version (SCID-P). Washington, DC, American Psychiatric Press, 1995
21. First M, Spitzer R, Gibbon M, Williams J, Benjamin L: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, DC, American Psychiatric Press, 1997
22. Pae CU, Patkar AA: Paroxetine: current status in psychiatry. Expert Rev Neurother 2007; 7:107-120
23. Foa EB, Rothbaum BO: Treating the Trauma of Rape: A Cognitive-Behavioral Therapy for PTSD. New York, Guilford, 1998
24. Guy W: ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW publ no ADM 76-338). Rockville, Md, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 218-222
25. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
26. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-326 (Pubitemid 23311543)
27. Nemeroff CB, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB: Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006; 40:1-21 (Pubitemid 43117523)
28. Brown H, Prescott R: Applied Mixed Models in Medicine. West Sussex, United Kingdom, John Wiley & Sons, 1999
29. Diggle PJ, Heagerty P, Liang KY, Zeger SL: Analysis of Longitudinal Data, 2nd ed. Oxford, United Kingdom, Oxford University Press, 2002
30. Hu MC, Pavlicova M, Nunes EV: Zero-inflated and hurdle models of count data with extra zeros: example from an HIV risk reduction intervention trial. Am J Drug Alcohol Abuse, 2011 (in press)
31. Hedeker D: Generalized linear mixed models, in Encyclopedia of Statistics in Behavioral Science. Edited by Everitt B, Howell D. New York, John Wiley & Sons, 2005
32. Selvin S: Statistical Analysis of Epidemiological Data. New York, Oxford University Press, 1996, pp 213-214
33. Foa EB, Kozak MJ: Emotional processing of fear: exposure to corrective information. Psychol Bull 1986; 99:20-35
34. Bradley R, Greene J, Russ E, Dutra L, Westen D: A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry 2005; 162:214-227 (Pubitemid 40216198)
35. Hembree EA, Foa EB, Dorfan NM, Street GP, Kowalski J, Tu X: Do patients drop out prematurely from exposure therapy for PTSD? J Trauma Stress 2003; 16:555-562 (Pubitemid 37541825)
36. Lurie I, Levine SZ: Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD. J Nerv Ment Dis 2010; 198:116-124
37. Norris FH, Friedman MJ, Watson PJ: 60,000 disaster victims speak, part II: summary and implications of the disaster mental health research. Psychiatry 2002; 65:240-260 (Pubitemid 35191282)
38. Neria Y, Nandi A, Galea S: Posttraumatic stress disorder following disasters: a systematic review. Psychol Med 2008; 38:467-480 (Pubitemid 351354882)
39. Marshall RD, Bryant R, Amsel L, Cook J, Suh EJ, Neria Y: The psychology of ongoing threat: relative risk appraisal, the September 11, 2001 attacks, and terrorism-related fears. Am Psychol 2007; 62:304-316
40. Feeny NC, Zoellner LA, Mavissakalian MR, Roy-Byrne PP: What would you choose? sertraline or prolonged exposure in community and PTSD treatment seeking women. Depress Anxiety 2009; 26:724-731
41. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, Maddock R, Hegel MT, Farfel G: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:1974-1981 (Pubitemid 33104101)